Development of next-generation designer cell with improved adipose-derived stem cells (ADSCs)

We are focusing on the development of novel therapies using adipose-derived stem cells (ADSCs) with enhanced functions via gene transfer. The response to treatment of ischemic stroke by autologous mesenchymal stem cells, including ADSCs, varies widely among individuals. In particular, ADSCs from elderly individuals have been reported to have decreased expression of hepatocyte growth factor (HGF), decreased levels of exosome miRNAs that promote nerve regeneration, and increased expression of exosome miRNAs associated with inflammation and aging. By introducing various genes, including HGF, we aim to create ADSCs designed to restore these impaired functions, accumulate efficiently at the site of injury, and exert sufficient therapeutic effect, thereby becoming a breakthrough therapy for ischemic stroke and multiple sclerosis.